Cite
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
MLA
Lassman, Andrew B., et al. “Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 23, Aug. 2022, pp. 2539–45. EBSCOhost, https://doi.org/10.1200/JCO.21.02543.
APA
Lassman, A. B., Hoang-Xuan, K., Polley, M.-Y. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., Souhami, L., Dinjens, W. N. M., Laack, N. N., Kouwenhoven, M. C. M., Fink, K. L., French, P. J., Macdonald, D. R., Lacombe, D., Won, M., Gorlia, T., Mehta, M. P., & van den Bent, M. J. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(23), 2539–2545. https://doi.org/10.1200/JCO.21.02543
Chicago
Lassman, Andrew B, Khê Hoang-Xuan, Mei-Yin C Polley, Alba A Brandes, J Gregory Cairncross, Johan M Kros, Lynn S Ashby, et al. 2022. “Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40 (23): 2539–45. doi:10.1200/JCO.21.02543.